Showing 31-40 of 648 results for "".
- Second Opinionshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0505SecondOpinion-pdf/31458/Addressing the AD-VaD Diagnostic Challenge in NeurologyIn the debate surrounding Alzheimer’s Disease (AD) versus vascular dementia (VaD) diagnosis, Dr. Geldmacher’s April 2005 article, “Diagnosing Alzheimer’s: Easy Answers vs. Right Answers,” ignited significant discourse. Dr. Geldmacher critiques c
Neuromuscular Notes: Genetic Testing for Neuromuscular Diseases
https://practicalneurology.com/diseases-diagnoses/neuromuscular/neuromuscular-notes-genetic-testing-for-neuromuscular-diseases/32181/This review presents a discussion on best practices for the clinical workup of suspected genetic neuromuscular diseases and provides an overview of how emerging technologies may aid diagnosis in the future.- CMS Expands Coverage for PET Imaging Related to Alzheimer Diseasehttps://practicalneurology.com/news/cms-expands-coverage-for-pet-imaging-for-diagnosing-alzheimer-disease/2470316/In a new policy change, the Centers for Medicare & Medicaid Services (CMS) have announced that they will cover the cost of PET imaging used for the diagnosis of Alzheimer disease (AD). The decision memo states that the CMS is eliminating previous restrictions which supported the cost of PET a
- Dementia Insightshttps://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN1005DementiaInsights-pdf/31386/Medicare’s Limited Approval of PET Scans in Dementia: Implications for Clinical PracticeIn September 2004, the Centers for Medicare and Medicaid Services (CMS) approved the use of positron emission tomography (PET) scans for dementia diagnosis, specifically to differentiate Alzheimer’s disease (AD)
- Oculomotor Test for Parkinson’s Disease Receives Breakthrough Device Designationhttps://practicalneurology.com/news/vision-system-receives-breakthrough-device-designation/2469088/The Food and Drug Administration (FDA) breakthrough device program was designed to streamline the market clearance and approval process for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Oculo
- National Treatment and Diagnostic Alzheimer Disease Registry Announcedhttps://practicalneurology.com/news/national-treatment-and-diagnostic-alzheimer-disease-registry-announced/2469739/Launch of a new national registry to collect real-world evidence on the diagnosis, treatment, and outcomes in Alzheimer disease (AD) has been announce. The registry is a joint initiative of The Alzheimer’s Association; the American College of Radiology; the American Society of Neuroradiolog
Video Case Challenge: Myotonia in a 53-Year-Old Man and His Teenage Daughter
https://practicalneurology.com/columns/practice-management/video-case-challenge-myotonia-in-a-53-year-old-man-and-his-teenage-daughter/30719/Watch the video at PracticalNeurology.net.Viewpoints: Can Big Data Elevate the Standard of Care in Neurology and Neurosurgery?
https://practicalneurology.com/columns/practice-management/viewpoints-can-big-data-elevate-the-standard-of-care-in-neurology-and-neurosurgery/30443/New Diagnostic Tool Approved for Evaluation of Dementia Patients
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/new-diagnostic-tool-approved-for-evaluation-of-dementia-patients/30778/Amyvid, which indicates levels of beta-amyloid plaques in the brain, can help guide the diagnosis of dementia.- Alzheimer’s Association Issues Its First Blood-Based Biomarker Guideline for Alzheimer’s Diagnosishttps://practicalneurology.com/news/alzheimers-association-issues-its-first-blood-based-biomarker-guideline-for-alzheimers-diagnosis/2475915/The Alzheimer’s Association has released its first clinical practice guideline with recommendations for the use of blood-based biomarker (BBM) tests in the diagnosis, treatment, and care of people with Alzheimer disease (AD). Presented at the 2025 meeting of the Alzheimer’s Association Internatio